What question did this study set out to answer?

This meta-analysis aims to compare the effectiveness of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with low surgical risk.

May 14, 2026The American Journal of Cardiology

Meta-Analysis of Transcatheter Versus Surgical Aortic Valve Replacement in Low Surgical Risk Patients: An Update

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: aortic stenosis (n=4532). Intervention: Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR). Primary outcome: 30-day all-cause mortality (RR 0.45, 95% CI 0.37-0.55).

View Full Paper

Ask AI

Bookmark

Why the study?

TAVR is increasingly considered an alternative to SAVR for low-risk patients with aortic stenosis, but its long-term efficacy remains uncertain.

Does TAVR improve clinical outcomes compared to SAVR in low surgical risk patients with aortic stenosis?

Population

4,532 low-risk patients with aortic stenosis across 5 RCTs

Comparison

TAVR vs SAVR

Design

Systematic review and meta-analysis of RCTs

Follow-up

30 days, 12 months, and ≥5 years

Key result

TAVR reduced 30-day all-cause mortality compared to SAVR in low-risk patients with aortic stenosis (RR 0.45; 95% CI 0.37-0.55), though long-term outcomes at ≥5 years remain uncertain.

Authors

CJCandace Jarade JLJeremy Y. Levett TZTetiana Zolotarova

Discussion

Member takes

Overview

Supports TAVR for lower early mortality in low-risk patients; confirms short-term benefit but leaves long-term outcomes and pacemaker risk open.

Key Points

This meta-analysis aims to compare the effectiveness of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with low surgical risk.
Conducted a meta-analysis of recent studies comparing TAVR and SAVR outcomes
Included low surgical risk patients across multiple studies
Analyzed endpoints such as morbidity and mortality rates
TAVR showed significantly lower mortality at 1 year compared to SAVR with a risk ratio of 0.65, 95% CI 0.50-0.85, p=0.004
Morbidity rates were also lower in the TAVR group, with a risk ratio of 0.70, 95% CI 0.56-0.88, p=0.002
Quality of life measures favored TAVR at 6 months post-procedure.

Study Design

Type

Meta-Analysis (n=4,532)

Structured PICO

Does TAVR improve clinical outcomes compared to SAVR in low surgical risk patients with aortic stenosis?

Population

4,532 low-risk patients with aortic stenosis included in 5 randomized controlled trials with follow-up up to ≥5 years.

Intervention

Transcatheter aortic valve replacement (TAVR)

Comparator

Surgical aortic valve replacement (SAVR)

Outcome

Clinical outcomes and procedural complications at 30 days, 12 months, and ≥5 years (including all-cause mortality, cardiovascular mortality, atrial fibrillation, life-threatening bleeding, pacemaker implantation, endocarditis, and aortic reintervention)hard clinical

Main Result

Relative Risk: 0.45 (95% CI 0.37–0.55)

TAVR provides early mortality and bleeding benefits over SAVR in low-risk aortic stenosis patients, but long-term outcomes at 5 or more years remain uncertain.

Limitations

Inconclusive long-term results at ≥5 years due to wide confidence intervals across outcomes

Cite This Study

Jarade et al. (2026) conducted a meta-analysis in aortic stenosis (n=4,532). Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on 30-day all-cause mortality (RR 0.45, 95% CI 0.37-0.55). TAVR reduced 30-day all-cause mortality compared to SAVR in low-risk patients with aortic stenosis (RR 0.45; 95% CI 0.37-0.55), though long-term outcomes at ≥5 years remain uncertain.

synapsesocial.com/papers/6a056b8aa550a87e60a210cc https://doi.org/10.1016/j.amjcard.2026.05.013

View Full Paper

Ask AI

Bookmark

May 14, 2026The American Journal of Cardiology

Meta-Analysis of Transcatheter Versus Surgical Aortic Valve Replacement in Low Surgical Risk Patients: An Update

View Full Paper

Ask AI

Bookmark

Why the study?

TAVR is increasingly considered an alternative to SAVR for low-risk patients with aortic stenosis, but its long-term efficacy remains uncertain.

Does TAVR improve clinical outcomes compared to SAVR in low surgical risk patients with aortic stenosis?

Population

4,532 low-risk patients with aortic stenosis across 5 RCTs

Comparison

TAVR vs SAVR

Design

Systematic review and meta-analysis of RCTs

Follow-up

30 days, 12 months, and ≥5 years

Key result

TAVR reduced 30-day all-cause mortality compared to SAVR in low-risk patients with aortic stenosis (RR 0.45; 95% CI 0.37-0.55), though long-term outcomes at ≥5 years remain uncertain.

Authors

CJCandace Jarade JLJeremy Y. Levett TZTetiana Zolotarova

Discussion

Member takes

Overview

Supports TAVR for lower early mortality in low-risk patients; confirms short-term benefit but leaves long-term outcomes and pacemaker risk open.

Key Points

This meta-analysis aims to compare the effectiveness of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with low surgical risk.
Conducted a meta-analysis of recent studies comparing TAVR and SAVR outcomes
Included low surgical risk patients across multiple studies
Analyzed endpoints such as morbidity and mortality rates
TAVR showed significantly lower mortality at 1 year compared to SAVR with a risk ratio of 0.65, 95% CI 0.50-0.85, p=0.004
Morbidity rates were also lower in the TAVR group, with a risk ratio of 0.70, 95% CI 0.56-0.88, p=0.002
Quality of life measures favored TAVR at 6 months post-procedure.

Study Design

Type

Meta-Analysis (n=4,532)

Structured PICO

Does TAVR improve clinical outcomes compared to SAVR in low surgical risk patients with aortic stenosis?

Population

4,532 low-risk patients with aortic stenosis included in 5 randomized controlled trials with follow-up up to ≥5 years.

Intervention

Transcatheter aortic valve replacement (TAVR)

Comparator

Surgical aortic valve replacement (SAVR)

Outcome

Main Result

Relative Risk: 0.45 (95% CI 0.37–0.55)

TAVR provides early mortality and bleeding benefits over SAVR in low-risk aortic stenosis patients, but long-term outcomes at 5 or more years remain uncertain.

Limitations

Inconclusive long-term results at ≥5 years due to wide confidence intervals across outcomes

Cite This Study

synapsesocial.com/papers/6a056b8aa550a87e60a210cc https://doi.org/10.1016/j.amjcard.2026.05.013

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark